TY - JOUR
T1 - Gonadotropin releasing hormone agonist treatment before hysterectomy for menorrhagia and uterine leiomyomas
AU - Vercellini, P.
AU - Bocciolone, L.
AU - Colombo, A.
AU - Vendola, N.
AU - Meschia, M.
AU - Bolis, G.
PY - 1993
Y1 - 1993
N2 - Objective. To investigate the effect of gonadotropin releasing hormone agonist (goserelin) treatment before hysterectomy for leiomyomata-associated menorrhagia. Design. Prospective, comparative, nonrandomized study. Setting. A teaching hospital of Milano University. Patients. Anemic women requiring hysterectomy for myoma-associated menorrhagia. Intervention. Six months' preoperative goserelin treatment (41 cases) or immediate surgery (92 controls). Main outcome measures. Abdominal/vaginal hysterectomy rate, number of transfusions, operating time, blood loss, complications, febrile morbidity, and days in hospital. Results. In the goserelin group mean hemoglobin rose (8.5 versus 13.3 g/dl) and mean uterine volume decreased (528 versus 251 ml). At preoperative pelvic exploration abdominal hysterectomy was indicated in 22 (54%) cases and 74 (80%) controls and vaginal hysterectomy in 19 (46%) and 18 (20%) (relative risk 3.6, 95% confidence interval 1.6 to 7.7; p = 0.001). No case required a transfusion whereas 51% of controls needed a total of 127 packed red cell units. Conclusions. In anemic women with menorrhagia and leiomyomas, gonadotropin releasing hormone agonist treatment before hysterectomy limited transfusion requirements and increased the vaginal procedure rate.
AB - Objective. To investigate the effect of gonadotropin releasing hormone agonist (goserelin) treatment before hysterectomy for leiomyomata-associated menorrhagia. Design. Prospective, comparative, nonrandomized study. Setting. A teaching hospital of Milano University. Patients. Anemic women requiring hysterectomy for myoma-associated menorrhagia. Intervention. Six months' preoperative goserelin treatment (41 cases) or immediate surgery (92 controls). Main outcome measures. Abdominal/vaginal hysterectomy rate, number of transfusions, operating time, blood loss, complications, febrile morbidity, and days in hospital. Results. In the goserelin group mean hemoglobin rose (8.5 versus 13.3 g/dl) and mean uterine volume decreased (528 versus 251 ml). At preoperative pelvic exploration abdominal hysterectomy was indicated in 22 (54%) cases and 74 (80%) controls and vaginal hysterectomy in 19 (46%) and 18 (20%) (relative risk 3.6, 95% confidence interval 1.6 to 7.7; p = 0.001). No case required a transfusion whereas 51% of controls needed a total of 127 packed red cell units. Conclusions. In anemic women with menorrhagia and leiomyomas, gonadotropin releasing hormone agonist treatment before hysterectomy limited transfusion requirements and increased the vaginal procedure rate.
KW - Gonadotropin releasing hormone agonists
KW - Hysterectomy
KW - Leiomyoma
KW - Menorrhagia
UR - http://www.scopus.com/inward/record.url?scp=0027217143&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027217143&partnerID=8YFLogxK
M3 - Article
C2 - 8392268
AN - SCOPUS:0027217143
VL - 72
SP - 369
EP - 373
JO - Acta Obstetricia et Gynecologica Scandinavica
JF - Acta Obstetricia et Gynecologica Scandinavica
SN - 0001-6349
IS - 5
ER -